Lung Function Study of Inhaled Glycopyrronium With BFF in Children With Asthma
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests whether adding a medication called glycopyrronium to a common asthma inhaler (BFF) helps children ages 4–12 breathe better. Researchers will measure lung function and compare two different doses of the added medication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has been diagnosed with asthma by a doctor
- Your child is 4 to less than 12 years old and weighs at least 14 kg (about 31 lbs)
- Your child is currently taking an inhaled corticosteroid plus one other asthma controller medicine, and this combination has been stable
- Your child's asthma control score on a standard test is 19 or higher
- Your child's lung function (measured by a breathing test) is at or below 95% of normal for their age
- Your child has not had a life-threatening asthma episode requiring a breathing tube or hospitalization for asthma
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study checks how glycopyrronium bromide works in children with asthma, including its safety and how well inhaler dosing is tolerated. It also uses breathing tests and inhaler technique checks to confirm your child meets key asthma and lung function requirements.
This study tests a new combination inhaler (fluticasone propionate and albuterol) for people with asthma age 12 and older. It helps see if this inhaler works better than a placebo in controlling asthma symptoms and preventing attacks.
This study looks at how asthma affects air flow and blood flow in your lungs. You may join if you use daily asthma control medicine and your breathing test shows room for improvement even after using a rescue inhaler.
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
This Phase 3 study compares a new inhaler (QMF149: indacaterol plus mometasone) against budesonide to see which works better and is safe for children ages 6 to under 12 with asthma. You may be able to join if your child is already on a stable low-dose steroid inhaler and still has symptoms.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
Hear when a new Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.